Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Later this year, likely in November, Johnson and Johnson will be spinning off its consumer products unit. Brands like Tylenol, Listerine, Band-Aid and Neutrogena will go under a new business ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson “should have known that the J&J Products contained harmful, deleterious, carcinogenic and inherently dangerous asbestos dust and fibers” and the products reportedly did not ...

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

Johnson & Johnson is a holding company ... and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines ...

Reviewed by Thomas Brock Fact checked by Vikki Velasquez Johnson & Johnson is one of the largest and most successful ...

In 2021, Johnson & Johnson unveiled a plan to spin off its consumer products division to focus on pharmaceuticals and medical technology. The company completed the Kenvue spinoff to shareholders ...